Eradication of established murine tumors using a novel cell-free vaccine: Dendritic cell-derived exosomes

Nature Medicine

Volumn 4, Issue 5, 1998, Pages 594-600

  Zitvogel, Laurence ^a   Regnault, Armelle ^b   Lozier, Anne ^a   Wolfers, Joseph ^a   Flament, Caroline ^a   Tenza, Danielle ^c   Ricciardi Castagnoli, Paola ^d   Raposo, Graça ^c   Amigorena, Sebastian ^b  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b INSTITUT CURIE   (France)

^c INSTITUT CURIE   (France)

^d UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; TUMOR VACCINE;

ADOPTIVE IMMUNOTHERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ANTIGEN PRESENTING CELL; ARTICLE; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CELL FREE SYSTEM; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; ERADICATION THERAPY; EXOCYTOSIS; FEMALE; INTRADERMAL DRUG ADMINISTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ADENOCARCINOMA; ANIMALS; ANTIGEN PRESENTATION; ANTIGENS, NEOPLASM; CANCER VACCINES; CELL-FREE SYSTEM; DENDRITIC CELLS; FEMALE; H-2 ANTIGENS; HISTOCOMPATIBILITY ANTIGENS CLASS I; HISTOCOMPATIBILITY ANTIGENS CLASS II; LYMPHOCYTE ACTIVATION; MAMMARY NEOPLASMS, ANIMAL; MAST-CELL SARCOMA; MICE; MICE, INBRED BALB C; MICE, INBRED DBA; MICE, NUDE; NEOPLASMS, EXPERIMENTAL; PEPTIDE FRAGMENTS; SUBCELLULAR FRACTIONS; T-LYMPHOCYTES, CYTOTOXIC;

ANIMALIA; MURINAE;

EID: 0031863853     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/nm0598-594     Document Type: Article

References (35)

1. Boon, T. & van der Bruggen, P. Human tumor antigens recognized by T lymphocytes. J. Exp. Med. 183, 725-729 (1996).
2. Lotze, M.T. et al. Cytokine gene therapy of cancer using IL-12: murine and clinical trials. J. Ann. NY Acad. Sci. 795, 440-454 (1996).
3. Restifo, N. The new vaccines: building viruses that elicit antitumor immunity. Curr. Opin. Immunol. 8, 658-663 (1996).
4. Tüting, T., DeLeo, A.B., Lotze, M. & Storkus, W. Genetically modified bone marrow-derived dendritic cells expressing tumor-associated viral or "self" antigens induce antitumor immunity in vivo. Eur. J. Immunol. 27, 2702-2707 (1997).
5. Cayeux, S. Influence of gene-modified (IL-7, IL-4, and B7) tumor cell vaccines on tumor antigen presentation. J. Immunol. 158, 2834-2841 (1997).
6. Iwasaki, A. et al. The dominant role of bone marrow-derived cells in CTL induction following plasmid DNA immunization at different sites. J. Immunol. 159, 11-14 (1997).
7. Hart, D.M.J. Dendritic cells: unique leukocyte populations which control the primary immune responses. Blood 90, 3245-3287 (1997).
8. Caux, C, Dezutter-Dambuyant, C., Schmitt, D. & Banchereau, J. GM-CSF and TNFα cooperate in the generation of dendritic Langherans cells. Nature 360, 258 (1992)
9. Pope M., Betjes, M., Hirmand, H., Hoffman, L. & Steinman, R. Both dendritic cells and memory T lymphocytes emigrate from organ cultures of human skin and form distinctive dendritic-T cell conjugates. J. Invest. Dermatol. 104, 11 (1995).
10. Inaba, K., Metlay, J., Crowley, M. & Steinman, R. Dendritic cells pulsed with protein antigens in vitro can prime antigen-specific, MHC-restricted T cell responses in situ. J. Exp. Med. 172, 631-640 (1990).
11. Steinman, R.M. The dendritic cell system and its role in immunogenicity. Annu. Rev. Immunol. 9, 271-296 (1991).
12. Ambe K., Mori, M. & Enjoji, M. S100 protein positive dendritic cells in colorectal adenocarcinomas. Distribution and relation to the clinical prognosis. Cancer 63, 496 (1989).
13. Maraskovsky, E. et al. Dramatic increase in the number of functionally mature dendritic cells in Flt3 ligand-treated mice: multiple dendritic cell subpopulations identified. J. Exp. Med. 184, 1953-1962 (1996).
14. Girolomoni, G. & Ricciardi-Castagnoli, P. Dendritic cells hold promise for immunotherapy. Immunol. Today 16, 102-104 (1997).
15. Germain, R., N. MHC-dependent antigen processing and peptide presentation: providing ligands for T lymphocyte activation. Cell 76, 287-299 (1994).
16. Pierre, P. et al. Developmental regulation of MHC class II transport in mouse dendritic cells. Nature 388, 787-792 (1997).
17. Cella, M., Engering, A., Pinet, V., Pieters, J. & Lanzavecchia, A. Inflammatory stimuli induce accumulation of MHC class II complexes on dendritic cells. Nature 388, 782-786 (1997).
18. Kleijmeer, M., J, Morkowski, S., Griffith, J., M, Rudensky, A., Y & Geuze, H., J. MHC class II compartments in human and mouse B lymphoblasts represent conventional endocytic compartments. J. Cell. Biol. 139, 639-649 (1997).
19. Raposo, G. et al. B lymphocytes secrete antigen presenting vesicles. J. Exp. Med. 183, 1161-1172 (1996).
20. Dufour, E. et al. Diversity of the cytotoxic melanoma-specific immune response. J. Immunol. 158, 3787-3795 (1997).
21. Mayordomo, J.I. et al. Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nature Med. 1, 1297-1302 (1995).
22. Winzler, C. et al. Maturation stages of mouse dendritic cells in growth factor-dependent long term cultures. J. Exp. Med. 185, 317-328 (1997).
23. Zitvogel, L. et al. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines. J. Exp. Med. 183, 87-97 (1996).
24. Warmer, C. et al. Induction of a cytolytic T-cell response in mice with a recombinant adenovirus coding for tumor antigen P815A. Int. J. Cancer 67, 303-310 (1996).
25. Zitvogel, L. et al. B7.1 costimulation markedly enhances IL-12 mediated antitumor immunity in vivo. Eur. J. Immunol. 26, 1335-1341 (1996).
26. Gabrilovich, D., I, Ciernik, F. & Carbone, D., P,. Dendritic cells in antitumor immune responses: defective antigen presentation in tumor-bearing hosts. Cell. Immunol. 170, 101 (1996).
27. Bender, A., Sapp, M., Schuler, G., Steinman, R.M. & Bhardwaj, N. Improved methods for the generation of dendritic cells from nonproliferating progenitors in human blood. J. Immunol. Methods. 196, 121-135 (1996).
28. Schmidt, W. et al. Cell-free tumor antigen peptide-based cancer vaccines. Proc. Natl. Acad. Sci. USA 94, 3262-3267 (1997).
29. Raposo, C., Kleijmeer, M., Posthuma, J., Slot, G. & Geuze, H. in Handbook of Exp. Immunol. 5th ed. (eds Herzenberg, L.A., Weir, D.M., Herzenberg, L.A. & Blackwell, C.) 1-11 (Science Inc. Maiden MA., 1997).
30. Sallusto, F. & Lanzavecchia, A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor a. J. Exp. Med. 179, 1109-1118 (1994).
31. Bockxmeer, F.v. & Morgan, E. Transferrin receptors during rabbit reticulocyte maturation. Biochim. Biophys. Acta 584, 76-83 (1979).
32. Stam, N., Spits, H. & Ploegh, H. Monoclonal antibodies raised against denaturated HLA-A and HLA-B locus H-chain permit biochemical characterization of certain HLA-C locus products. J. Immunol. 137, 2299-2306 (1986).
33. Metzelaar, M. et al. CD63 antigen: a novel lysosomal membrane glycoprotem, cloned by a screening procedure for intracellular antigens in eukaryotic cells. J. Biol. Chem. 266, 3239-3245 (1991).
34. Mayordomo, J.I. et al. Bone-marrow derived DC serve as potent adjuvants for peptide-based antitumor vaccines. Stem Cells 15, 94-103 (1997).
35. Caux, C. et al. B70/B7.2 is identical to CD86 and is the major functional ligand for CD28 expressed on human dendritic cells. J. Exp. Med. 180, 1841-1847 (1994).